Astria Therapeutics Inc(ATXS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -2.15 | Insider Own | 12.34% | Shs Outstand | 56.4M | Perf Week | 0.32% |
| Market Cap | 0.72B | Forward P/E | - | EPS next Y | -8.13% | Insider Trans | - | Shs Float | 50.3M | Perf Month | -1.95% |
| Enterprise Value | 0.59B | PEG | - | EPS next Q | -0.54 | Inst Own | 81.23% | Short Float | 8.32% | Perf Quarter | 3.45% |
| Income | -0.12B | P/S | 1011.36 | EPS this Y | -31.75% | Inst Trans | -18.62% | Short Ratio | 3.86 | Perf Half Y | 88.32% |
| Sales | 0.00B | P/B | 5.15 | EPS next 5Y | -5.63% | ROA | -39.16% | Short Interest | 4.18M | Perf YTD | -3.9% |
| Book/sh | 2.44 | P/C | 3.15 | EPS past 3/5Y | 59.12% 34.65% | ROE | -43.15% | 52W High | -5.34% ($13.29) | Perf Year | 66.18% |
| Cash/sh | 3.99 | P/FCF | - | Sales past 3/5Y | - | ROIC | -52.49% | 52W Low | 253.87% ($3.56) | Perf 3Y | -11.22% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -2.74% | Gross Margin | - | Volatility(W/M) | 2.11% 1.68% | Perf 5Y | -22.63% |
| Dividend TTM | - | EV/Sales | 831.16 | Sales Y/Y TTM | - | Oper. Margin | -19335.69% | ATR (14) | 0.23 | Perf 10Y | -96.78% |
| Dividend Ex-Date | - | Quick Ratio | 10.78 | EPS Q/Q | -28.56% | Profit Margin | -17567.99% | RSI (14) | 46.09 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 10.78 | Sales Q/Q | - | SMA20 | -1.78% ($12.81) | Beta | 0.25 | Target Price | $13 |
| Payout | - | Debt/Eq | 0.02 | Earnings | 2025/11/12 | SMA50 | -1.3% ($12.75) | Rel Volume | 0 | Prev Close | $12.58 |
| Employees | 78 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | -40.77% -93.38% | SMA200 | 51.97% ($8.28) | Avg Volume(3M) | 1.08M | Price | $12.58 |
| IPO | 2015/6/25 | Option/Short | No/No | Trades | 0 | Volume | - | Change | - |
🧬 Astria Therapeutics (ATXS) is a US biotech company developing treatments for rare immune and allergic diseases. Its lead candidate is an antibody drug targeting hereditary angioedema, currently advancing through clinical stages with the goal of reducing attack frequency via long-acting administration. As a clinical-stage company with no commercial revenue yet, pipeline progress is the key driver of its valuation.
Over the past 1 year, on the higher side
5% below its 1-year high.
Traded less than usual. That is 0% of its average volume.
ATXS has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -31.8% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $101,136. Peers typically go for $199.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -22.6%. The S&P 500 did +61% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 81.2%.
Tap to view numbers
It ranks #188 of 598 in the industry
Based on market cap of $718M.
CADL#185 Candel Therapeutics Inc $726M PER - 
NVCT#186 Nuvectis Pharma Inc $723M PER - 
ZVRA#187 Zevra Therapeutics Inc $722M PER 10.2 ATXS#188 Astria Therapeutics Inc $718M PER - 
IMMX#188 Immix Biopharma Inc $710M PER - 
FAQ
What kind of company is ATXS?
ATXS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ATXS?
The market cap of ATXS is approximately $718M, ranking 2,854 within its sector.
What is the 52-week high and low for ATXS?
ATXS has recorded a 52-week high of $13.29 and a low of $3.56.
